PDF(Pubmed)
Abstract：
UNASSIGNED: Treatment outcome data of stereotactic radiosurgery (SRS) for vestibular schwannomas (VS) in patients ≥75 years (late elderly) are lacking. Approximately 39% of patients ≥75 years with VS were reported to experience severe facial palsy after surgical removal. This study compared the treatment outcomes post-SRS for VS between patients ≥75 and 65-74 years (early elderly).
UNASSIGNED: Of 453 patients who underwent gamma knife SRS for VS, 156 were ≥65 years old. The late and early elderly groups comprised 35 and 121 patients, respectively. The median tumor volume was 4.4 cc, and the median radiation dose was 12.0 Gy.
UNASSIGNED: The median follow-up periods were 37 and 56 months in the late and early elderly groups, respectively. Tumor volume control was observed in 27 (88%) and 95 (83%) patients (P = 0.78), while additional procedures were required in 2 (6%) and 6 (6%) patients (P = 1.00) in the late and early elderly groups, respectively. At the 60th and 120th months post-SRS, the cumulative tumor control rates were 87%, 75%, 85%, and 73% (P = 0.81), while the cumulative clinical control rates were 93% and 87%, 95%, and 89% (P = 0.80), in the late and early elderly groups, respectively. In the early elderly group, two patients experienced facial pain, and one experienced facial palsy post-SRS; there were no adverse effects in the late elderly group (both P = 1.00).
UNASSIGNED: SRS is effective for VS and beneficial in patients ≥75 years old as it preserves the facial nerve.
UNASSIGNED: Of 453 patients who underwent gamma knife SRS for VS, 156 were ≥65 years old. The late and early elderly groups comprised 35 and 121 patients, respectively. The median tumor volume was 4.4 cc, and the median radiation dose was 12.0 Gy.
UNASSIGNED: The median follow-up periods were 37 and 56 months in the late and early elderly groups, respectively. Tumor volume control was observed in 27 (88%) and 95 (83%) patients (P = 0.78), while additional procedures were required in 2 (6%) and 6 (6%) patients (P = 1.00) in the late and early elderly groups, respectively. At the 60th and 120th months post-SRS, the cumulative tumor control rates were 87%, 75%, 85%, and 73% (P = 0.81), while the cumulative clinical control rates were 93% and 87%, 95%, and 89% (P = 0.80), in the late and early elderly groups, respectively. In the early elderly group, two patients experienced facial pain, and one experienced facial palsy post-SRS; there were no adverse effects in the late elderly group (both P = 1.00).
UNASSIGNED: SRS is effective for VS and beneficial in patients ≥75 years old as it preserves the facial nerve.
摘要：
■在≥75岁（老年晚期）的患者中，缺乏立体定向放射外科（SRS）治疗前庭神经鞘瘤（VS）的结果数据。据报道，超过75岁的VS患者中约有39％在手术切除后出现严重的面神经麻痹。这项研究比较了≥75和65-74岁（早期老年）的VS患者在SRS后的治疗结果。
■在453例接受了VS伽玛刀SRS的患者中，年龄≥65岁156例。晚期和早期老年组包括35和121名患者，分别。中位肿瘤体积为4.4cc，中位辐射剂量为12.0Gy。
■晚期和早期老年组的中位随访时间分别为37和56个月，分别。在27例（88%）和95例（83%）患者中观察到肿瘤体积控制（P=0.78）。在晚期和早期老年组中，有2例（6％）和6例（6％）患者需要额外的手术（P=1.00），分别。在SRS之后的第60个月和第120个月，累积肿瘤控制率为87%，75%,85%,73%(P=0.81)，而累积临床控制率为93%和87%，95%,89%(P=0.80)，在晚期和早期老年群体中，分别。在早期老年群体中，两名患者出现面部疼痛,1人在SRS后出现面神经麻痹;晚期老年组没有不良反应(P=1.00).
■SRS对VS有效，对≥75岁的患者有益，因为它保留了面神经。
■在453例接受了VS伽玛刀SRS的患者中，年龄≥65岁156例。晚期和早期老年组包括35和121名患者，分别。中位肿瘤体积为4.4cc，中位辐射剂量为12.0Gy。
■晚期和早期老年组的中位随访时间分别为37和56个月，分别。在27例（88%）和95例（83%）患者中观察到肿瘤体积控制（P=0.78）。在晚期和早期老年组中，有2例（6％）和6例（6％）患者需要额外的手术（P=1.00），分别。在SRS之后的第60个月和第120个月，累积肿瘤控制率为87%，75%,85%,73%(P=0.81)，而累积临床控制率为93%和87%，95%,89%(P=0.80)，在晚期和早期老年群体中，分别。在早期老年群体中，两名患者出现面部疼痛,1人在SRS后出现面神经麻痹;晚期老年组没有不良反应(P=1.00).
■SRS对VS有效，对≥75岁的患者有益，因为它保留了面神经。
